Since then, six more ICIs have been approved by the FDA, exclusively targeting the T cell co-inhibitory programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling pathway (3, 4), with clinical indications across 19 different cancer types and two tissue-agnostic conditions (Fig. 1). This evidence concerns the gene CD274 and cancer.